PubblicazioniPublications    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   HomePubblicazioni
Pubblicazioni IGM

Current treatment strategies for inhibiting mTOR in cancer

Autori

Chiarini F, Evangelisti C, McCubrey JA, Martelli AM.

Riferimenti

TRENDS IN PHARMACOLOGICAL SCIENCES 36(2) 124-135, 2015

Autori CNR

CHIARINI, EVANGELISTI

Moduli

Abstract

Mammalian target of rapamycin (mTOR) is a Ser/Thr kinase that regulates a wide range of functions, including cell growth, proliferation, survival, autophagy, metabolism, and cytoskeletal organization. mTOR activity is dysregulated in several human disorders, including cancer. The crucial role of mTOR in cancer cell biology has stimulated interest in mTOR inhibitors, placing mTOR on the radar of the pharmaceutical industry. Several mTOR inhibitors have already undergone clinical trials for treating tumors, without great success, although mTOR inhibitors are approved for the treatment of some types of cancer, including advanced renal cell carcinoma. However, the role of mTOR inhibitors in cancer treatment continues to evolve as new compounds are continuously being disclosed. Here we review the three classes of mTOR inhibitors currently available for treating cancer patients. Moreover, we highlight efforts to identify markers of resistance and sensitivity to mTOR inhibition that could prove useful in the emerging field of personalized medicine.Copyright 2014 Elsevier Ltd. All rights reserved.

Link all articolo

http://www.sciencedirect.com/science/article/pii/S0165614714001953

Parole Chiave

Note

Indietro


Copyright © 2014 Home